Takeda to Divest Non-Core Assets for $562 million

September 11, 2020
Pharmaceutical Technology Editors

Takeda is divesting its portfolio of select, non-core prescription pharmaceutical products sold in Europe and Canada to Cheplapharm, a German pharmaceutical company.

Takeda announced on Sept. 8, 2020 that it is divesting its portfolio of select, non-core prescription pharmaceutical products sold in Europe and Canada to Cheplapharm, a German pharmaceutical company.

Under the terms of the agreement, Takeda will receive an upfront payment of $562 million, while Cheplapharm obtains Takeda’s portfolio of non-core prescription pharmaceutical products including cardiovascular/metabolic and anti-inflammatory products, and calcium, a Takeda press release said.

“These divestments represent another important milestone in our portfolio simplification and optimization strategy as we position Takeda for continued success across our five key business areas: gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience,” said Giles Platford, president, EUCAN, Takeda, in the press release. “We are pleased to have found a partner in Cheplapharm who shares our commitment to patient care and has the experience and resources to continue investing in these important products well into the future for the benefit of patients.”

“Today’s announcement allows Takeda to continue to be patient-focused as we streamline and optimize our portfolio according to our global long-term strategy,” added Costa Saroukos, chief financial officer, Takeda, in the press release. “While the trusted products included in the sale address key patient needs in these countries, they are outside of our core business areas of focus. We are confident that Cheplapharm is the right partner to ensure patients continue to have access to these products.”

Source: Takeda